BioAtla (NASDAQ:BCAB) PT Lowered to $5.00 at JMP Securities

BioAtla (NASDAQ:BCAB) had its target price lowered by JMP Securities from $12.00 to $5.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a market outperform rating on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $7.00 price objective on shares of BioAtla in a research note on Wednesday, May 15th.

BioAtla Stock Down 18.6 %

Shares of BioAtla stock opened at $1.71 on Thursday. The company has a market capitalization of $82.29 million, a PE ratio of -0.69 and a beta of 1.23. The stock’s fifty day moving average is $2.84 and its two-hundred day moving average is $2.42. BioAtla has a 52 week low of $1.24 and a 52 week high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Tuesday, March 26th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. As a group, research analysts anticipate that BioAtla will post -1.72 earnings per share for the current year.

Hedge Funds Weigh In On BioAtla

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of BioAtla in the 1st quarter worth $103,000. Price T Rowe Associates Inc. MD purchased a new position in BioAtla in the 1st quarter worth $45,000. Acadian Asset Management LLC lifted its position in BioAtla by 57.6% during the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock worth $532,000 after acquiring an additional 56,748 shares during the period. Vanguard Group Inc. raised its position in BioAtla by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock worth $7,221,000 after buying an additional 17,667 shares during the last quarter. Finally, Chase Investment Counsel Corp purchased a new stake in BioAtla in the first quarter valued at $263,000. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.